Back to Navigation

Paul Offit Dialogue | Munk Debates

October 21, 2022

Paul Offit Dialogue

The Bivalent COVID-19 Booster: do the benefits outweigh the risks?

Guests
Paul Offit

About this episode

Health Canada, the FDA, and the CDC have approved COVID bivalent vaccines to anyone over the age of 12. This booster is different from previous COVID shots, targeting multiple strains of the novel coronavirus, including Omicron sub variants. And while the vaccine is being widely distributed, some epidemiologists are sounding the alarm. Dr. Paul Offit, Director of the Vaccine Education Center and attending physician in the Division of Infectious Diseases at Children’s Hospital of Philadelphia, is one of two members on the FDA committee who voted against advising all adults over the age of 12 to get the jab. Offit joins Rudyard Griffiths for a talk about the Bivalent COVID-19 boosters, who should be getting them, and where more study is warranted.

 

Share:

Guests

Paul Offit

“The data that we were shown didn’t make it clear that the bivalent vaccine was any better…boosters are a value, but I don’t see why the bivalent one is better than what we have already been getting.”

Paul Offit

“The data that we were shown didn’t make it clear that the bivalent vaccine was any better…boosters are a value, but I don’t see why the bivalent one is better than what we have already been getting.”

Paul A. Offit, MD, is Director of the Vaccine Education Center and professor of pediatrics in the Division of Infectious Diseases at Children’s Hospital of Philadelphia. He is the Maurice R. Hilleman Professor of Vaccinology at the Perelman School of Medicine at the University of Pennsylvania.

Dr. Offit is an internationally recognized expert in the fields of virology and immunology, and was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention. He is a member of the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee, and a founding advisory board member of the Autism Science Foundation and the Foundation for Vaccine Research, a member of the Institute of Medicine and co-editor of the foremost vaccine text, Vaccines.

Dr. Offit has published more than 150 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq®, recommended for universal use in infants by the CDC. For this achievement, Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases, and was honored by Bill and Melinda Gates during the launch of their Foundation’s Living Proof Project for global health.

Comments